Akt-dependent and -independent mechanisms of mTOR regulation in cancer

Regan M. Memmott, Phillip A. Dennis

Research output: Contribution to journalArticle

Abstract

The protein kinase mTOR (mammalian target of rapamycin) is a critical regulator of cellular metabolism, growth, and proliferation. These processes contribute to tumor formation, and many cancers are characterized by aberrant activation of mTOR. Although activating mutations in mTOR itself have not been identified, deregulation of upstream components that regulate mTOR are prevalent in cancer. The prototypic mechanism of mTOR regulation in cells is through activation of the PI3K/Akt pathway, but mTOR receives input from multiple signaling pathways. This review will discuss Akt-dependent and -independent mechanisms of mTOR regulation in response to mitogenic signals, as well as its regulation in response to energy and nutrient-sensing pathways. Preclinical and clinical studies have demonstrated that tumors bearing genetic alterations that activate mTOR are sensitive to pharmacologic inhibition of mTOR. Elucidation of novel pathways that regulate mTOR may help identify predictive factors for sensitivity to mTOR inhibitors, and could provide new therapeutic targets for inhibiting the mTOR pathway in cancer. This review will also highlight pharmacologic approaches that inhibit mTOR via activation of the AMP-activated protein kinase (AMPK), an important inhibitor of the mTOR pathway and an emerging target in cancer.

Original languageEnglish (US)
Pages (from-to)656-664
Number of pages9
JournalCellular Signalling
Volume21
Issue number5
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Sirolimus
Neoplasms
AMP-Activated Protein Kinases
Protein Kinase Inhibitors
Phosphatidylinositol 3-Kinases
Protein Kinases

Keywords

  • Akt
  • AMPK
  • Cancer
  • mTOR

ASJC Scopus subject areas

  • Cell Biology

Cite this

Akt-dependent and -independent mechanisms of mTOR regulation in cancer. / Memmott, Regan M.; Dennis, Phillip A.

In: Cellular Signalling, Vol. 21, No. 5, 05.2009, p. 656-664.

Research output: Contribution to journalArticle

Memmott, Regan M. ; Dennis, Phillip A. / Akt-dependent and -independent mechanisms of mTOR regulation in cancer. In: Cellular Signalling. 2009 ; Vol. 21, No. 5. pp. 656-664.
@article{30cbdcf18a604471b0a5af6fe5aaae31,
title = "Akt-dependent and -independent mechanisms of mTOR regulation in cancer",
abstract = "The protein kinase mTOR (mammalian target of rapamycin) is a critical regulator of cellular metabolism, growth, and proliferation. These processes contribute to tumor formation, and many cancers are characterized by aberrant activation of mTOR. Although activating mutations in mTOR itself have not been identified, deregulation of upstream components that regulate mTOR are prevalent in cancer. The prototypic mechanism of mTOR regulation in cells is through activation of the PI3K/Akt pathway, but mTOR receives input from multiple signaling pathways. This review will discuss Akt-dependent and -independent mechanisms of mTOR regulation in response to mitogenic signals, as well as its regulation in response to energy and nutrient-sensing pathways. Preclinical and clinical studies have demonstrated that tumors bearing genetic alterations that activate mTOR are sensitive to pharmacologic inhibition of mTOR. Elucidation of novel pathways that regulate mTOR may help identify predictive factors for sensitivity to mTOR inhibitors, and could provide new therapeutic targets for inhibiting the mTOR pathway in cancer. This review will also highlight pharmacologic approaches that inhibit mTOR via activation of the AMP-activated protein kinase (AMPK), an important inhibitor of the mTOR pathway and an emerging target in cancer.",
keywords = "Akt, AMPK, Cancer, mTOR",
author = "Memmott, {Regan M.} and Dennis, {Phillip A.}",
year = "2009",
month = "5",
doi = "10.1016/j.cellsig.2009.01.004",
language = "English (US)",
volume = "21",
pages = "656--664",
journal = "Cellular Signalling",
issn = "0898-6568",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Akt-dependent and -independent mechanisms of mTOR regulation in cancer

AU - Memmott, Regan M.

AU - Dennis, Phillip A.

PY - 2009/5

Y1 - 2009/5

N2 - The protein kinase mTOR (mammalian target of rapamycin) is a critical regulator of cellular metabolism, growth, and proliferation. These processes contribute to tumor formation, and many cancers are characterized by aberrant activation of mTOR. Although activating mutations in mTOR itself have not been identified, deregulation of upstream components that regulate mTOR are prevalent in cancer. The prototypic mechanism of mTOR regulation in cells is through activation of the PI3K/Akt pathway, but mTOR receives input from multiple signaling pathways. This review will discuss Akt-dependent and -independent mechanisms of mTOR regulation in response to mitogenic signals, as well as its regulation in response to energy and nutrient-sensing pathways. Preclinical and clinical studies have demonstrated that tumors bearing genetic alterations that activate mTOR are sensitive to pharmacologic inhibition of mTOR. Elucidation of novel pathways that regulate mTOR may help identify predictive factors for sensitivity to mTOR inhibitors, and could provide new therapeutic targets for inhibiting the mTOR pathway in cancer. This review will also highlight pharmacologic approaches that inhibit mTOR via activation of the AMP-activated protein kinase (AMPK), an important inhibitor of the mTOR pathway and an emerging target in cancer.

AB - The protein kinase mTOR (mammalian target of rapamycin) is a critical regulator of cellular metabolism, growth, and proliferation. These processes contribute to tumor formation, and many cancers are characterized by aberrant activation of mTOR. Although activating mutations in mTOR itself have not been identified, deregulation of upstream components that regulate mTOR are prevalent in cancer. The prototypic mechanism of mTOR regulation in cells is through activation of the PI3K/Akt pathway, but mTOR receives input from multiple signaling pathways. This review will discuss Akt-dependent and -independent mechanisms of mTOR regulation in response to mitogenic signals, as well as its regulation in response to energy and nutrient-sensing pathways. Preclinical and clinical studies have demonstrated that tumors bearing genetic alterations that activate mTOR are sensitive to pharmacologic inhibition of mTOR. Elucidation of novel pathways that regulate mTOR may help identify predictive factors for sensitivity to mTOR inhibitors, and could provide new therapeutic targets for inhibiting the mTOR pathway in cancer. This review will also highlight pharmacologic approaches that inhibit mTOR via activation of the AMP-activated protein kinase (AMPK), an important inhibitor of the mTOR pathway and an emerging target in cancer.

KW - Akt

KW - AMPK

KW - Cancer

KW - mTOR

UR - http://www.scopus.com/inward/record.url?scp=60549096247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549096247&partnerID=8YFLogxK

U2 - 10.1016/j.cellsig.2009.01.004

DO - 10.1016/j.cellsig.2009.01.004

M3 - Article

C2 - 19166931

AN - SCOPUS:60549096247

VL - 21

SP - 656

EP - 664

JO - Cellular Signalling

JF - Cellular Signalling

SN - 0898-6568

IS - 5

ER -